Amgen’s Bispecific Blinatumomab May Be Ready For Leukemia Filing
This article was originally published in Pharmaceutical Approvals Monthly
Single-arm, Phase II data in relapsed acute lymphoblastic leukemia could suffice, firm says, for what would be the first-ever U.S. approval of an engineered bispecific antibody.
You may also be interested in...
Rolling BLA for MK-3475 accepted for priority review with a PDUFA date of Oct. 28. Merck is undertaking or plans trials testing the anti-PD-1 candidate in 10 types of cancer and is seeking response signals in another 20 tumor types.
FDA approves Biogen’s long-acting hemophilia drug Alprolix and lifts clinical hold on Curis’ cancer drug CUDC-427, but Amgen’s announcement that its melanoma vaccine T-VEC failed to improve survival clouds its chances with the agency.
Given high complete response rates in early studies showcased at the American Society of Hematology’s recent annual meeting, acute lymphoblastic leukemia is a likely launch indication for chimeric antigen receptor immunotherapy. But while the results in B-cell malignancies are very promising so far, autologous CAR therapies are complex, and toxicities need to be carefully managed.